bioMérieux S.A
Research bioMérieux S.A (EYWN) on Bullrun: market cap EUR 8.03B, P/E 20.4, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEYWN
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 8.03B
- P/E20.4
- Dividend yield1.4%
- Financial periodFY2025
- RevenueEUR 4.07B
- Revenue growth2.3%
- Net incomeEUR 397.50M
- Free cash flowEUR 453.10M
- Gross margin56.7%
Valuation Snapshot
latest market cap is EUR 8.03B; P/E is 20.4; dividend yield is 1.4%.
About bioMérieux S.A
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR);
Frequently asked questions
What is bioMérieux S.A's market cap?
bioMérieux S.A's market capitalization is EUR 8.03B.
What is bioMérieux S.A's P/E ratio?
bioMérieux S.A's price-to-earnings (P/E) ratio is 20.4.
Does bioMérieux S.A pay a dividend?
bioMérieux S.A has a dividend yield of 1.4%.
What does bioMérieux S.A do?
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments.